Viking Therapeutics, Inc. (VKTX): Matthew W Foehr , director of Viking Therapeutics, Inc. purchased 20,000 shares on Apr 13, 2016. The Insider buying transaction was reported by the company on Apr 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.24 per share for a total value of $24,800.00 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Viking Therapeutics Inc is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $6. The Rating was issued on Apr 7, 2016.
Institutional Investors own 0.43% of Viking Therapeutics Inc shares.
Viking Therapeutics Inc: On Monday, Apr 11, 2016 heightened volatility was witnessed in Viking Therapeutics Inc which led to swings in the share price. The shares opened for trading at $1.35 and hit $1.41 on the upside , eventually ending the session at $1.34, with a gain of 10.74% or 0.13 points. The heightened volatility saw the trading volume jump to 30,79,068 shares. The 52-week high of the share price is $10.23 and the company has a market cap of $13 M . The 52-week low of the share price is at $1.06.
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211 which is an orally available drug candidate under a Phase II clinical trial. Its second clinical program is focused on the development of molecule agonists of the thyroid receptor beta (TRB) for adrenoleukodystrophy (ALD) and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH). The Company is also engaged in developing VK2809 and VK0214 for the treatment and potential prophylaxis of ALD. Its VK0612 is an orally available Phase IIb-ready drug candidate for type 2 diabetes. The Company’s preclinical programs are focused on identifying erythropoietin receptor (EPOR) agonists for the treatment of anemia and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1 (DGAT-1) for the treatment of obesity and dyslipidemia.